ESTRO 2025 - Abstract Book

S2286

Interdisciplinary – Health economics & health services research

ESTRO 2025

Clinician perspectives should be considered alongside existing evidence in shaping clinical trial design, with LC emphasised as a key endpoint in SBRT commissioning discussions.

Keywords: SBRT, oligometastatic breast cancer, survey

1679

Proffered Paper Advancing the ESTRO-HERO cost tool for innovative treatment costing and flexible resource allocation Quentin Bouchez 1 , Barbara Vanderstraeten 1,2 , Yolande Lievens 1,2 1 Department of Human Structure and Repair, Ghent University, Ghent, Belgium. 2 Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium Purpose/Objective: The Health Economics in Radiation Oncology (ESTRO-HERO) project introduced a cost-accounting model in 2019, utilizing time-driven activity-based costing (TD-ABC), to estimate radiotherapy resource costs and needs at national level, and support national resource planning and reimbursement in radiation oncology. [1] Used by radiotherapy professionals of over 30 countries, the ESTRO-HERO tool received feedback from national-level initiatives and departmental experiences, highlighting shortcomings to be addressed. This abstract outlines an upgrade of the ESTRO-HERO model, focusing on improving its ability to incorporate future innovations and advancing national and institutional application. Material/Methods: The upgrade process started with a comprehensive list of experienced shortcomings, followed by an in-depth analysis of the model’s structure and code to uncover the reasons for these shortcomings and potential additional areas needing improvement. Each identified shortcoming was categorized according to its underlying cause in the model: decisions about model design, cost allocation of resources, definition of core elements (see Table 1). Solutions for each category were discussed and developed, resulting in a beta-version of the upgraded model.